QUALIGEN THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCKQualigen Therapeutics, Inc. • March 31st, 2021 • Pharmaceutical preparations
This Warrant is the Warrant issued to the Holder in exchange for the corresponding “Series C Preferred Stock Warrant” which had been issued on _______, 20__ by Qualigen, Inc. and which corresponding “Series C Preferred Stock Warrant” (as previously adjusted through the time of the merger) had been assumed by the Company pursuant to a May 22, 2020 merger involving Qualigen, Inc. By accepting this Warrant, the Holder acknowledges that such corresponding Qualigen, Inc. “Series C Preferred Stock Warrant” is no longer exercisable, and that such corresponding “Series C Preferred Stock Warrant” has instead been replaced by this Warrant.
NOVATION AGREEMENTNovation Agreement • March 31st, 2021 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations
This Novation Agreement (this “Agreement”) is made on July 29, 2020 between Advanced Cancer Therapeutics, LLC, a Kentucky limited liability company (“ACT”), Qualigen, Therapeutics, Inc., a Delaware corporation (“QLGN”) and Qualigen, Inc., a Delaware corporation (“Qualigen”). This Agreement is made with respect to the License Agreement dated December 17, 2018 between ACT and Qualigen (the “License Agreement”). The parties intend this Agreement to constitute a novation of the License Agreement.
SECOND AMENDMENT TO WARRANT AGENCY AGREEMENTWarrant Agency Agreement • March 31st, 2021 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDMENT TO WARRANT AGENCY AGREEMENT made as of November 9, 2020 (this “Amendment”), amends that certain Warrant Agency Agreement, dated September 29, 2017 (as previously amended by a First Amendment dated May 1, 2018, the “Warrant Agreement”), between Ritter Pharmaceuticals, Inc., a Delaware corporation, now known as Qualigen Therapeutics, Inc. (the “Company”), and Equiniti Trust Company as the successor Warrant Agent under the Warrant Agreement. In addition, Equiniti Trust Company, as the distributee of Corporate Stock Transfer, Inc. upon the voluntary dissolution of Corporate Stock Transfer, Inc., is entering into this Amendment on behalf of Corporate Stock Transfer, Inc. Capitalized terms that are used and not defined in this Amendment shall have the meanings assigned to them in the Warrant Agreement.
